Corrado TARELLA, M.D. Personal data Date of birth: January 22, 1951 Place of birth: Bricherasio (Torino), Italy Citizenship : Italian Identity card: AC9131287 Status: married, one daughter Present Position: Full Professor of Hematology, Dip. Medicina & Oncologia Sperimentale, University of Torino Director, S.C. a direzione Universitaria “Ematologia e Terapie Cellulari” A.O. Ordine Mauriziano-Umberto I Largo Turati 62, 10128 Torino – Italy Director, Laboratory of Hematology Molecular Biotechnology Center (MBC) Via Nizza 52, 10126 Torino – Italy phone, HOSPITAL: 0039-011-508.2949; 508.2175 LAB at MBC: 0039-011-670.6444 portable: 347-4315493 fax: 0039-011-508.2446 e-mail: corrado.tarella@unito.it Education - High school degree, Istituto Sociale of Torino, 1969 - Medical Doctor degree, University of Torino, 1975 - Postgraduate degree in Hematology, University of Milan, 1979 - Postgraduate degree in Clinical Oncology, University of Torino, 1998 Professional record - Internship, Department of Internal Medicine (Director: Prof. F. Gavosto), University of Torino, 1976-1978 - Fellowship on Cancer Research, "Comitato Piemontese Gigi Ghirotti" - Italy, 1978 - Post-doctoral research fellow at Laboratory of Tumor Cell Biology (Director: Prof. R.C. Gallo), National Cancer Institute, N.C.I., Bethesda, MD U.S.A., 1978-1980 - Served in the Italian Army 1980-81 - Assistant and then Associate Director, Department of Medicine and Experimental Oncology, Hematology Division (Director: Prof. A. Pileri), S. Giovanni Hospital of Torino - Italy, 1981-1998 - Visiting physician as Associate Staff at the Bone Marrow Transplantation Program (Director: Prof. G.W. Santos), The Johns Hopkins Oncology Center, Baltimore, MD U.S.A., April - July 1984 - Associate Professor of Hematology at the University of Torino, with clinical responsibility at the Department of Medicine and Experimental Oncology, Hematology Division, S. Giovanni Hospital - Torino - 1998- March 2002 - Full Professor of Hematology at the University of Torino, with clinical responsibility at the Department of Medicine and Experimental Oncology, Hematology Division, S. Giovanni Hospital - Torino - March 2002-2008 - In charge of the Bone Marrow Transplantation program of the Hematology Division, at the BG.M.T. Unit of S. Giovanni Hospital of Torino, 1986-2000 - In charge of the Lymphoma Treatment program at the Hematology Division, S. Giovanni Hospital of Torino, 2000-2008 - Director, Laboratory of Hematology, at Molecular Biotechnology Center (MBC) in Torino, March 2008 - present - Director, University Division of Hematology and Cell Therapy at the Mauriziano Hospital in Torino, October 2008 - present - Lecturer on “Experimental Oncology”, Postgraduate School of Oncology, University of Torino, 1983-87 - Lecturer on “Biology of Hemopoietic stem cells”, Postgraduate School of Hematology, University of Torino, 1987-present Professional Societies - Italian Society of Hematology - Italian Society of Experimental Hematology - Italian Bone Marrow Transplantation Group (GITMO) - Co-ordinator of the National autograft for the Italian Bone Marrow Transplantation Group (GITMO), 1998-2001 - In 2002 he founded the Italian Multicenter study Group GITIL (Italian Group for Innovative Therapies in Lymphoma). So far, 16 Italian Hematology/Oncology Institutions are affiliated to the GITIL. Prof. Tarella was elected President of the GITIL in October 2002 Publications- 112 original contributions to peer-reviewed international journals - 63 reviews or book chapters - No. of Citations of the original papers: 4,200 (as of December 2009) Major fields of interest - Thalassemia and hemoglobinopathies - differentiation and proliferation of hematopoietic progenitor and stem cells - peripheral blood progenitor cell mobilization and harvest for transplantation purposes - high-dose chemotherapy followed by autografting in lymphoma and myeloma patients - allogeneic transplantation in lymphoma patients - application of PCR-based methods for the detection of minimal residual disease in B-cell malignancies - clinical use of monoclonal antibodies in combination with conventional or high-dose chemotherapy in patients with B-cell malignancies - in vitro manipulation of both hematopoietic stem cell (HSC) and mesechymal stem cells (MSC) - clinical use of BM-derived cells to repair non-hematopoietic damaged tissues - cell senescence pathway in normal and neoplastic disorders - at present, he is among the principal investigators of several Italian multicenter studies, including: Ø conventional chemo-immunotherapy; Ø high-dose chemotherapy with autograft or allograft in B-cell malignancies; Ø Lymphoproliferative disease following solid organ transplant (PTLD); Ø Use of BM-derived stem cells for non-hematopoietic tissue regeneration, in neurologic degenerative diseases, in orthopedic surgical procedures, in ischemia-induced tissue injury - in order to perform clinical studies focused on innovative therapies for lymphoma patients, he founded the multicenter GITIL study group, of whom he is the current President Main Grants- since 1988, he is in charge of the transplant and lymphoma programs at the Hematology Division, S. Giovanni Hospital and University of Torino, supported by grants from C.N.R. (National Research Council) and from A:I:R:C: (Italian Association for Cancer Research) - 1989, recipient of a grant from Regione Piemonte for a study program on “Phenotypic and functional evaluation of clonogenic cells in acute leukemia” - 1995, recipient of a grant from C.N.R. (National Research Council), for a study program on “High-dose chemotherapy with ex-vivo purged PBPC autograft in follicular lymphomas” - 1999 - 2007: recipient of grants from M.U.R.S.T. (Italian National Department of University and Scientific Research, cofinanziamento-60%) - 2002: recipient of a grant from M.U.R.S.T. (grant: cofinanziamento-40% for a collaborative study project coordinated by Prof. P. Comoglio) - 2005: recipient of a grant from Regione Piemonte – “Ricerca Sanitaria finalizzata” - 2006: recipient of a grant from M.U.R.S.T. (grant: cofinanziamento-40% for a collaborative study project coordinated by Prof. C. Tarella on the use of BM-derived stem cells for non-hematopoietic tissue regeneration) - 2007: recipient of a grant from Regione Piemonte – “Ricerca Sanitaria finalizzata” - 2009: recipient of a grant from M.U.R.S.T. (grant: cofinanziamento-40% for a collaborative study project coordinated by Prof. C. Tarella on the “Factors affecting the senescence pathway of hematopoietic stem cells”)
SELECTED SCIENTIFIC PUBLICATIONS 1. Tarella C, Ferrero D, Gallo E, Pagliardi GL, Ruscetti FW. Induction of differentiation of HL-60 cells by dimethylsulfoxide; evidence for a stochastic model not linked to the cell division cycle. Cancer Res 1982, 42: 445-449. (I.F. 7.656) (Citations: 128) 2. Tarella C, Ruscetti FW, Poiesz BJ, Woods A, Gallo RC. Factors that affect human hemopoiesis are produced by T-cell growth factor dependent and independent cultured T-cell leukemia-lymphoma cells. Blood 1982, 59: 1330-1336. (I.F. 10.432) (Citations: 47) 3. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autransplantation. The Lancet 1989, 8663: 580-585 (I.F. 25.800) (Citations: 724) 4. Tarella C, Ferrero D, Bregni M, Siena S, Gallo E, Pileri A, Gianni AM. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991, 27: 22-27. (I.F. 4.475) (Citations: 91) 5. Tarella C, Boccadoro M, Omedè P, Bondesan P, Caracciolo D, Frieri R, Bregni m, Siena S, Gianni AM, Pileri A. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transpl 1993, 11: 271-277. (I.F. 3.400) (Citations: 55) 6. Corradini P, Astolfi M, Cherasco C, Caracciolo A, Pileri A, Tarella C. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997, 89: 724-731 (I.F. 10.370) (Citations: 128) 7. Gianni AM, Bregni M, Siena S, Brambilla, Di Nicola M, Lombardi F, Gandola F, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 1997, 336: 1290-1297 (I.F. 52.589) (Citations: 348) 8. Tarella C, Castellino C, Locatelli F, Caracciolo D, CorradiniP, Falda M, ovarino A, Tassi V, Pileri A. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998, 21: 401-407 (I.F. 3.000) (Citations: 49) 9. Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A, Rossi G, Novero D, Gavarotti P, Pileri A. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000, 14: 740-747 (I.F. 6.924) (Citations: 31) 10. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli , Tarella C, Pileri A, Bonadonna G, Gianni AM. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000, 96: 854-61 (I.F. 10.896) (Citations: 155) 11. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Pileri A, Gianni AM, Tarella C. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001;15: 1941-9. (I.F. 8.634) (Citations: 38) 12. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiatelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Zambello R, Chisesi T, Di Renzo N, Musso M, Vivaldi P , De Crescenzo A, Gallamini A, Salvi F, Santini G, Astolfi M, Drandi D, Pileri A, Tarella C. High Rates Of Clinical And Molecular Remissions In Follicular Lymphoma Patients Receiving High-Dose Sequential Chemotherapy And Autografting At Diagnosis: A Multicenter, Prospective Study By The Gruppo Italiano Trapianto Midollo Osseo (Gitmo). Blood 2002, 100(5): 1559-65 (I.F. 10.896) (Citations: 50) 13. Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM and Levis A. High-Dose Sequential Chemotherapy And Peripheral Blood Progenitor Cell (PBPC) Autografting In Refractory/Relapsed Hodgkin's Lymphoma: A Multicenter Study Of The Intergruppo Italiano Linfomi (Iil) Showing Prolonged Disease-Free Survival In Patients Treated At First Relapse. Cancer, 2003; 97(11): 2748-2759 (I.F. 4.632) (Citations: 31) 14. Corradini P, Ladetto M°, Zallio F, Astolfi M, Rizzo E, Cuttica A, Rosato R, Farina L, Boccadoro M, Benedetti F, Pileri A, Tarella C. Long-Term Follow-Up Of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy And Autografting: Evidence That Durable Molecular And Clinical Remission Can Be Frequently Attained Only In Follicular Subtypes. J Clin Oncol, 2004; 22(8):1460-8 (I.F. 15.484) (Citations: 56) 15. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini Mt, Bregni M, Narni F, Patriarca F, Boccadoro M, Gianni AM, Tarella C. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation. J Clin Oncol, 2004; 22(11): 2172-6. (I.F. 17.157) (Citations: 58) 16. Ricca I, Compagno M, Ladetto M, Rocci A, Dell’Aquila M, Omedè P, De Marco F, D’Antico S, Caracciolo D, Ferrero D, Carlo-Stella C, Tarella C. Marked Telomere Shortening In Mobilized Peripheral Blood Progenitor Cells (PBPC) Following Two Tightly-Spaced High-Dose Chemotherapy Courses With G-CSF. Leukemia 2005; 19(4): 644-51. (I.F. 8.634) (Citations: 11) 17. Gaia S, Smedile A, Omedè P, Olivero A, Sanavio F, Balzala F, Ottobrelli A, Abate ML, Marzano A, Rizzetto M and Tarella C. Feasibility and safety of G-CSF administration to induce Bone Marrow–Derived Cell mobilization in patients with end stage liver disease. J Hepatol 2006; 45(1): 13-19 (I.F. 6.073) (Citations: 24) 18. Rocci A, Ricca I, Dellacasa C, Longoni P, Compagno M, Francese R, Lobetti Bodoni C, Manzini P, Caracciolo D, Boccadoro M, Ferrero D, Ladetto M, Carlo-Stella C, Tarella C. Long-Term Lymphoma Survivors Following High-Dose Chemotherapy And Autograft: Evidence Of Permanent Telomere Shortening In Myeloid Cells, Associated With Marked Reduction Of Bone Marrow Hematopoietic Stem Cell Reservoir Exp Hematol 2007; 35(4): 673-681 (I.F. 3.147) (Citations: 12) 19. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM, on behalf of the Gruppo Italiano Terapie Innovative nei Linfomi (GITIL) Prolonged survival in poor-risk Diffuse Large B-cell Lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Leukemia 2007; 21(8): 1802-11. (I.F. 8.634) (Citations: 11) 20. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial. Blood. 2007 Jun 20; [Epub ahead of print] 110: 2316-23 (I.F. 10.896) (Citations: 42) 21. Corradini P, Dodero, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni A M, Tarella C. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323. (I.F. 8.634) (Citations: 24) 22. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an over-all survival advantage. Blood. 2008 Apr 15; 111(8):4004-13 (I.F. 10.896) (Citations: 22) 23. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera P, Pizzolo G, Gianni AM, Rambaldi A. Rituximab improves the therapeutic efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter GITIL survey of 745 patients. J Clin Oncol 2008, 26(19): 3166-75 (I.F. 13.598) Citations: 5) 24. Ruella M, Rocci A, Ricca I, Carniti C, Bodoni CL, Ladetto M, Caracciolo D, Boccadoro M, Carlo-Stella C, Corradini P, Tarella C. Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplant 2010 Mar;45(3):505-12 (I.F. 3.400) 25. Tarella C, Rutella S, Gualandi F, Melazzini M, Scimè R, Petrini M, Moglia C, Ulla M, Omedé P, Bella VL, Corbo M, Silani V, Siciliano G, Mora G, Caponnetto C, Sabatelli M, Chiò A. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy 2010; 12(1): 50-9 (I.F. 3.471) (Citations: 1) |
